Atopic Dermatitis and Food Triggers

Atopic dermatitis (AD) can cause red, itchy skin flares linked to food allergies, but only 30% of people with AD have food triggers. It’s important to see a doctor before eliminating foods. Young children are more prone to AD, but about 90% outgrow it by age five. A food allergy causes hives, not AD, and…

Read More

Study Suggests Mind-Body Benefits of GLP-1s

An analysis of health records found that people using GLP-1 medications for weight loss or diabetes were less likely to develop new diagnoses of depression or anxiety. This correlation was observed among both diabetics and non-diabetic weight loss patients, especially with the drug tirzepatide. While promising, the study’s findings are not conclusive, and it’s unclear…

Read More

Best Eye Drops For 2024: Revitalize Your Vision

The article explains that dry eyes can cause discomfort and blurred vision, and provides tips for selecting the best eye drops for dry eyes. It also lists the best eye drops for dry eyes, red eyes, and allergies, and provides a brief description of each product. The article emphasizes the importance of consulting an eye…

Read More

CDSCO Panel Tells Boehringer Ingelheim

The Central Drugs Standard Control Organization (CDSCO) panel has requested further study on the safety and effectiveness of using tenecteplase at a dosage of 0.25 mg/kg for treating acute ischemic stroke. This request was made to the pharmaceutical company Boehringer Ingelheim. The study will focus on evaluating the potential risks and benefits of this treatment…

Read More

Limiting Cyberattack Blast Radius for Healthcare SaaS

Attorneys filed suit against Johns Hopkins University and its health system, alleging that they failed to secure IT systems, resulting in a theft of sensitive patient data. The lawsuit mentions a Zero-Day flaw in the MOVEit file transfer system. Other healthcare providers, including Harris Health, have also been affected by this flaw. As more hospitals…

Read More

Adding Fruquintinib to Paclitaxel Improves PFS in Gastric, GEJ Cancer

Fruquintinib plus paclitaxel has shown promising results as a second-line treatment option for patients with advanced gastric or gastroesophageal junction (GEJ) cancer. The combination improved responses and progression-free survival (PFS) compared to paclitaxel alone, and there was a trend toward improved overall survival (OS) with fruquintinib. The FRUTIGA trial included 703 patients with advanced gastric…

Read More

What we’ve learned from the Aduhelm mess

STAT publishes selected Letters to the Editor in response to First Opinion essays for robust, good-faith discussion. Jason Karlawish’s article on Aduhelm’s approval process raises concerns about the roles and incentives of pharmaceutical companies and the FDA. John Haaga supports Karlawish’s points and advocates for public funding of FDA and NIH research for objectivity. Adina…

Read More
error: Content is protected !!